Mereo BioPharma Group plc
Fourth Floor
One Cavendish Place
London W1G 0QF
United Kingdom
October 20, 2020
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Division of Corporation Finance Office of Life Sciences |
| Re: | Mereo BioPharma Group plc (the “Company”) |
Registration Statement on Form F-3
Filed on October 6, 2020
File No. 333-249341
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company respectfully requests that the effectiveness of the registration statement on Form F-3 (File No. 333-249341) of the Company (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 04:00 p.m., Eastern Time, on October 21, 2020 or as soon thereafter as may be practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Mayer Brown LLP, by calling David S. Bakst at (212) 506-2551. The Company hereby authorizes Mr. Bakst to orally modify or withdraw this request for acceleration.
| Very truly yours, | ||
| MEREO BIOPHARMA GROUP PLC | ||
| By: | /s/ Denise Scots-Knight | |
| Name: | Denise Scots-Knight | |
| Title: | Chief Executive Officer | |
Cc: David S. Bakst
Mayer Brown LLP
Charles Sermon
Mereo BioPharma Group plc